CETP inhibition: Does the future look promising?

Current Cardiology Reports

Volumn 13, Issue 6, 2011, Pages 559-565

  Toth, Peter P ^a  

^a Preventive Cardiology   (United States)

Author keywords

Apolipoprotein A I; Apolipoprotein B; Atherosclerosis; CETP; Cholesterol; Cholesteryl ester transfer protein; Coronary artery disease; High density lipoprotein; Low density lipoprotein receptor; Polymorphism; Reverse cholesterol transport; Scavenger receptor BI; Very low density lipoprotein

Indexed keywords

ANACETRAPIB; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TORCETRAPIB;

ACUTE CORONARY SYNDROME; ALDOSTERONE BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; BICARBONATE BLOOD LEVEL; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DYSLIPIDEMIA; ELECTROLYTE DISTURBANCE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; ISCHEMIC HEART DISEASE; LIVER TOXICITY; LOSS OF FUNCTION MUTATION; MONOTHERAPY; MYOPATHY; POTASSIUM BLOOD LEVEL; PROTEIN FUNCTION; RISK REDUCTION; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VASODILATATION;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; INCIDENCE; MALE; QUINOLINES; RISK FACTORS;

EID: 81255136680     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-011-0218-x     Document Type: Article

References (48)

1. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol 1988; 4 Suppl A:5A-10A.
2. S Yusuf S Hawken S Ounpuu, et al. 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 937 952 15364185 10.1016/S0140-6736(04)17018-9
3. AR Sharrett CM Ballantyne SA Coady, et al. 2001 Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study Circulation 104 1108 1113 11535564 10.1161/hc3501.095214 1:CAS:528:DC%2BD3MXotlWgur0%3D
4. T Vaisar S Pennathur PS Green, et al. 2007 Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL J Clin Invest 117 746 756 17332893 10.1172/JCI26206 1:CAS:528: DC%2BD2sXis12htLs%3D These investigators demonstrated that the HDL proteosome is characterized by over 75 different enzymes, apolipoproteins, globulins, and other proteins that impact HDL functionality
5. PP Toth 2010 Activation of intracellular signaling systems by high-density lipoproteins J Clin Lipidol 4 376 381 21122681 10.1016/j.jacl.2010. 08.011
6. H Brewer 2004 High-density lipoproetins: a new potential therapeutic target for the prevention of cardiovascular disease Arterioscl Thromb Vascul Biol 24 387 391 10.1161/01.ATV.0000121505.88326.d2 1:CAS:528: DC%2BD2cXitl2ku7g%3D
7. AV Khera M Cuchel M de la Llera-Moya, et al. 2011 Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 127 135 21226578 10.1056/NEJMoa1001689 1:CAS:528:DC%2BC3MXmvFarsA%3D%3D These investigators demonstrated in convincing fashion that HDL functionality as measured by capacity for driving RCT impacts risk for CHD more than measurements of HDL-C
8. PP Toth D Potter E Ming 2010 Abstract 12055: Prevalence of Lipid Abnormalities in the United States: The National Health and Nutrition Examination Survey 2003-2006 Circulation 122 A12055
9. E Bruckert M Baccara-Dinet F McCoy J Chapman 2005 High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients Curr Med Res Opin 21 1927 1934 16368042 10.1185/030079905X74871 1:CAS:528: DC%2BD28XhtF2jurY%3D
10. CA Aguilar-Salinas G Olaiz V Valles, et al. 2001 High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey J Lipid Res 42 1298 1307 11483632 1:CAS:528:DC%2BD3MXlvFeksLg%3D
11. Z Li R Yang G Xu T Xia 2005 Serum lipid concentrations and prevalence of dyslipidemia in a large professional population in Beijing Clin Chem 51 144 150 15539467 10.1373/clinchem.2004.038646 1:CAS:528:DC%2BD2MXlt1ymsw%3D%3D
12. C Baigent A Keech PM Kearney, et al. 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267 1278 16214597 10.1016/S0140-6736(05)67394-1 1:CAS:528:DC%2BD2MXhtVOlu7fM
13. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) 2001 Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) Jama 285 2486 2497 10.1001/jama.285.19.2486
14. CM Ballantyne JS Raichlen SJ Nicholls, et al. 2008 Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden Circulation 117 2458 2466 18378607 10.1161/CIRCULATIONAHA.108.773747 1:CAS:528:DC%2BD1cXltl2hsb8%3D
15. SJ Nicholls EM Tuzcu I Sipahi, et al. 2007 Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis Jama 297 499 508 17284700 10.1001/jama.297.5.499 1:CAS:528:DC%2BD2sXhs1Wis7k%3D
16. B Brown X Zhao M Cheung 2007 Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence J Clin Lipidol 1 88 94 21291671 10.1016/j.jacl.2007.02.004
17. I Goldenberg U Goldbourt V Boyko, et al. 2006 Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial) Am J Cardiol 97 466 471 16461038 10.1016/j.amjcard.2005.09.078 1:CAS:528:DC%2BD28Xhtlaqt7w%3D
18. Y Cui DJ Watson CJ Girman, et al. 2009 Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study) Am J Cardiol 104 829 834 19733719 10.1016/j.amjcard.2009.05.020 1:CAS:528:DC%2BD1MXhtV2rt7%2FE
19. SJ Robins D Collins JT Wittes, et al. 2001 Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 1585 1591 11268266 10.1001/jama.285.12.1585 1:CAS:528:DC%2BD3MXivVajt7s%3D
20. • The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J 2011; 161:471-477 e2. This much awaited trial was recently terminated by the US National Heart, Lung, and Blood Institute due to futility. No separation of outcome curves between treatment groups could be discerned. Because of these findings, the role of niacin therapy in patients with low serum levels of HDL-C has been called into question. Another trial testing the therapeutic value of niacin therapy in patients with low HDL-C and CAD (HPS2-THRIVE) remains underway.
21. PP Toth 2010 Pharmacomodulation of high-density lipoprotein metabolism as a therapeutic intervention for atherosclerotic disease Curr Cardiol Rep 12 481 487 20740329 10.1007/s11886-010-0136-3
22. X Qiu A Mistry MJ Ammirati, et al. 2007 Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules Nat Struct Mol Biol 14 106 113 17237796 10.1038/nsmb1197
23. A Inazu ML Brown CB Hesler, et al. 1990 Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation N Engl J Med 323 1234 1238 2215607 10.1056/NEJM199011013231803 1:STN:280:DyaK3M%2FhsFamtw%3D%3D
24. K Hirano S Yamashita N Nakajima, et al. 1997 Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity Arterioscler Thromb Vasc Biol 17 1053 1059 9194754 10.1161/01.ATV.17.6.1053 1:STN:280:DyaK2szjvVWqsQ%3D%3D
25. A Thompson E Di Angelantonio N Sarwar, et al. 2008 Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk JAMA 299 2777 2788 18560005 10.1001/jama.299.23.2777 1:CAS:528:DC%2BD1cXns1Sktb4%3D Important meta-analysis demonstrating that loss-of-function mutations in CETP do correlate with modest reductions in risk for CHD
26. ME Brousseau JJ O'Connor Jr JM Ordovas, et al. 2002 Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial Arterioscler Thromb Vasc Biol 22 1148 1154 12117730 10.1161/01.ATV.0000024566.57589.2E 1:CAS:528:DC%2BD38XlsFShu7c%3D
27. B Agerholm-Larsen BG Nordestgaard R Steffensen, et al. 2000 Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene Circulation 101 1907 1912 10779455 1:CAS:528:DC%2BD3cXjt1Crsro%3D
28. B Agerholm-Larsen A Tybjaerg-Hansen P Schnohr, et al. 2000 Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study Circulation 102 2197 2203 11056092 1:CAS:528:DC%2BD3cXptVSjurw%3D
29. SE Borggreve HL Hillege BH Wolffenbuttel, et al. 2005 The effect of cholesteryl ester transfer protein -629 C-> A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides J Clin Endocrinol Metab 90 4198 4204 15840744 10.1210/jc.2005-0182 1:CAS:528: DC%2BD2MXmtlCiurg%3D
30. JJ Regieli JW Jukema DE Grobbee, et al. 2008 CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction Eur Heart J 29 2792 2799 18957472 10.1093/eurheartj/ehn465 1:CAS:528:DC%2BD1cXhsFCrsLvF
31. RS Vasan MJ Pencina SJ Robins, et al. 2009 Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community Circulation 120 2414 2420 19948972 10.1161/ CIRCULATIONAHA.109.872705 1:CAS:528:DC%2BD1MXhsFSqtb3E This analysis performed in the world's most important epidemiologic cohort demonstrates an inverse relationship between CETP activity and risk for CHD-related events
32. SE Nissen JC Tardif SJ Nicholls, et al. 2007 Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 1304 1316 17387129 10.1056/NEJMoa070635 1:CAS:528:DC%2BD2sXjsFGnsrY%3D
33. SJ Nicholls EM Tuzcu DM Brennan, et al. 2008 Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) Circulation 118 2506 2514 19029466 10.1161/CIRCULATIONAHA.108.790733 1:CAS:528:DC%2BD1cXhsVerur3L
34. Kastelein JJ, van Leuven SI, Burgess L et al. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. N Engl J Med 2007.
35. ML Bots FL Visseren GW Evans, et al. 2007 Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 370 153 160 17630038 10.1016/S0140-6736(07)61088-5 1:CAS:528:DC%2BD2sXns12jtLg%3D
36. PJ Barter M Caulfield M Eriksson, et al. 2007 Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2109 2122 17984165 10.1056/NEJMoa0706628 1:CAS:528:DC%2BD2sXhtlGns7bL
37. CR Sirtori G Mombelli 2010 Cholesteryl ester transfer protein antagonism by drugs-a poor choice Clin Chem 56 1550 1553 20802095 10.1373/clinchem.2010. 147389 1:CAS:528:DC%2BC3cXht12is7zP
38. L Yvan-Charvet F Matsuura N Wang, et al. 2007 Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL Arterioscler Thromb Vasc Biol 27 1132 1138 17322101 10.1161/ATVBAHA.106.138347 1:CAS:528:DC%2BD2sXktFagtLs%3D
39. MJ Forrest D Bloomfield RJ Briscoe, et al. 2008 Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br J Pharmacol 154 1465 1473 18536749 10.1038/bjp.2008.229 1:CAS:528:DC%2BD1cXptVajs7g%3D
40. MA Connelly TJ Parry EC Giardino, et al. 2010 Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition J Cardiovasc Pharmacol 55 459 468 20051879 1:CAS:528: DC%2BC3cXmtlamsLk%3D
41. Y Xing A Cohen G Rothblat S Sankaranarayanan G Weibel L Royer, et al. 2011 Aldosterone production in human adrenocortical cells is stimulated by high-density lipoprotein 2 (HDL2) through increased expression of aldosterone synthase (CYP11B2) Endocrinology. 152 3 751 763 21239432 10.1210/en.2010-1049 1:CAS:528:DC%2BC3MXktVGrsrc%3D
42. EA Stein ES Stroes G Steiner, et al. 2009 Safety and tolerability of dalcetrapib Am J Cardiol 104 82 91 19576325 10.1016/j.amjcard.2009.02.061 1:CAS:528:DC%2BD1MXotFCitL8%3D
43. EA Stein EM Roth JM Rhyne, et al. 2010 Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial Eur Heart J 31 480 488 20097702 10.1093/eurheartj/ehp601 1:CAS:528:DC%2BC3cXitFejsbg%3D
44. CP Cannon S Shah HM Dansky, et al. 2010 Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2406 2415 21082868 10.1056/NEJMoa1009744 1:CAS:528:DC%2BC3cXhsF2ltLfL
45. M Ranalletta KK Bierilo Y Chen, et al. 2010 Biochemical characterization of cholesteryl ester transfer protein inhibitors J Lipid Res 51 2739 2752 20458119 10.1194/jlr.M007468 1:CAS:528:DC%2BC3cXhtVOltr%2FP
46. EJ Niesor C Magg N Ogawa, et al. 2010 Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport J Lipid Res 51 3443 3454 20861162 10.1194/jlr.M008706 Elegant experimental demonstration of how dalcetrapib potentiates the regeneration of poorly lipdated HDL particles (pre-β HDL) and increases rates of RCT
47. GG Schwartz AG Olsson CM Ballantyne, et al. 2009 Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome Am Heart J 158 896 901 e3 19958854 10.1016/j.ahj.2009.09.017 1:CAS:528:DC%2BD1MXhsFagsr7K
48. JJ Kastelein R Duivenvoorden J Deanfield, et al. 2011 Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation Curr Med Res Opin 27 141 150 21128879 10.1185/03007995.2010.536207 1:CAS:528:DC%2BC3cXhsFOjsb%2FF